ArticleOncogene2023

ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study.

Charlotte Rose Lemech et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.